Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice
- 3 August 2007
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 34 (12) , 2024-2036
Abstract
EphA2 receptor tyrosine kinase is significantly overexpressed in a wide variety of cancer types. High EphA2 expression has been correlated with increased metastatic potential and poor patient survival. Although many recent reports have focused on blocking the EphA2 signaling pathway in cancer, the in vivo imaging of EphA2 has not yet been investigated.Keywords
This publication has 41 references indexed in Scilit:
- In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin αvβ3Cancer Research, 2006
- Further investigations of morpholino pretargeting in mice—establishing quantitative relations in tumorEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA DeliveryCancer Research, 2005
- EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer TherapeuticsCurrent Cancer Drug Targets, 2005
- Dosimetry of internal emitters.2005
- Eph Receptor Tyrosine Kinases in Tumor and Tumor MicroenvironmentCurrent Pharmaceutical Design, 2004
- Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior.2002
- The ephrins and Eph receptors in angiogenesisCytokine & Growth Factor Reviews, 2002
- Molecular Distinction and Angiogenic Interaction between Embryonic Arteries and Veins Revealed by ephrin-B2 and Its Receptor Eph-B4Cell, 1998
- Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso.1995